{
    "clinical_study": {
        "@rank": "109379", 
        "arm_group": [
            {
                "arm_group_label": "ASC-01", 
                "arm_group_type": "Experimental", 
                "description": "The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The dose of 0mg/100mg (Placebo/Sertraline Combination \uff09will be orally administered once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination)\n      compared to sertraline monotherapy in patients with major depressive disorders who have\n      responded incompletely to sertraline monotherapy."
        }, 
        "brief_title": "Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are either inpatients or outpatients.\n\n          -  Patients who are able to understand necessary information for giving consent to\n             undergo examinations, observations, and evaluations specified in this clinical\n             protocol, and who are able to give written consent based on a full understanding of\n             the trial.\n\n          -  Patients who have been given a diagnosis of \"Major Depressive Disorder, Single\n             Episode\" or \"Major Depressive Disorder, Recurrent\" according to the DSM-5 and who\n             have a current episode of major depression that has been continuing for at least 8\n             weeks\n\n          -  Patients with a HAM-D 17 total score of 18 or more at the Screening Period evaluation\n\n        Exclusion Criteria:\n\n          -  Female patients of childbearing potential who wish to become pregnant during the\n             trial period or within 4 weeks after completion or discontinuation of the trial\n\n          -  Pregnant or breast-feeding female patients, or female patients who may be pregnant\n\n          -  Patients judged to be intolerant to all antidepressant (including drugs not used for\n             their current episodes of major depression) based on their treatment history\n\n          -  Patients who have had electroconvulsive therapy\n\n          -  Patients who have enrolled in a clinical trial of other drugs or medical devices\n             within 1 month before the time of informed consent\n\n          -  Patients who have a medical history suggesting a risk of developing serious adverse\n             events or symptoms that may hinder efficacy/safety evaluation (eg, symptoms of\n             fibromyalgia, or premenstrual syndrome etc that overlap with depressive symptoms)\n\n          -  Patients with complications or a history of diabetes mellitus, or patients who have\n             been judged to be diabetic\n\n               -  fasting blood glucose level \u2265 126 mg/dL\n\n               -  2-hour glucose level in 75-g oral glucose tolerance test (OGTT) \u2265 200 mg/dL\n\n               -  non-fasting blood glucose level \u2265 200 mg/dL\n\n               -  HbA1c [NGSP level] \u2265 6.5%\n\n          -  Patients who are undergoing treatment for thyroid disease (except for patients whose\n             disease has been stabilized with drug therapy for 3 months or longer before the time\n             of informed consent)\n\n          -  Patients who have a history of neuroleptic malignant syndrome or serotonin syndrome\n\n          -  Patients who have a history of seizure disorder (eg, epilepsy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046564", 
            "org_study_id": "031-12-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASC-01", 
                "intervention_name": "ASC-01", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto Region", 
                    "country": "Japan"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder", 
        "overall_contact": {
            "last_name": "Drug Information Center", 
            "phone": "+81-3-6361-7314"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Kyoji Imaoka, Mr", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Malaysia: Ministry of Health", 
                "Taiwan: Ministry of Health and Welfare", 
                "Korea: Ministry of Food and Drug Safety"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Montgomery-Asberg Depression Rating Scale (MADRS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Hamilton Depression Rating Scale (HAM-D)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 14 weeks"
        }, 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}